

Appendix 4E

PRELIMINARY FINAL REPORT 12 MONTHS ENDED 30 JUNE 2010

Details of the reporting period and the previous corresponding period

Name of entity

Holista CollTech Limited (formerly CollTech Australia Limited)

ABN	Reporting period	Previous corresponding period
24 094 515 992	12 months ended 30/06/10	12 months ended 30/06/09

Results for announcement to the market

Revenues from continuing activities	Down	1.1%	to	A\$6,235,000
Loss from ordinary activities after tax attributable to members	Up	900%	to	A\$620,000
Net Loss for the year attributable to Members	Up	2,384%	to	A\$1,540,000
Dividends	Amount per security		Franked amount per security	
Interim dividend	Nil		Nil	
Final Dividend	Nil		Nil	
Record date for determining entitlements to the dividend	N/A			
<p>The difference between the Loss from ordinary activities and the Net Loss above is due to the write-off of intangible assets.</p> <p>On 10 July 2009, Holista Biotech Sdn Bhd of Malaysia completed a reverse take-over of Colltech Australia Ltd. In a reverse take-over situation, it is the continuing company's accounts that form the basis of the consolidation.</p> <p>As such, the comparative figures for the previous year ended 30 June 2009 reflect only the results of the Malaysia operations and excludes the net loss of the Australian operations of A\$1,920,000, whereas the figures for the current year ended 30 June 2010 reflect the consolidated accounts comprising the Malaysian operations as well as the Australian operations.</p>				

REVIEW OF OPERATIONS

The reverse take over was successfully completed on 10th of July 2009 and the Australian operations have been rationalized, resulting in cost reductions and improved efficiencies in marketing, sales and R & D.

The main Malaysian entities are active in the health supplement business and their products are sold in pharmacies throughout Malaysia.

The company and its subsidiaries is also research based biotech with patents filed or pending in the areas of food ingredients and herbal products in health enhancement and protection.

The company has active R & D collaborations in Australia, Malaysia, India, UK and USA.

The results for the year ended 30 June 2010 show a consolidation loss of A\$1,540,000 compared to a consolidation loss of A\$62,000 for the previous year.

This was mainly attributed to:-

- A write down of intangible asset due to the expiry of several patents – A\$ 920,000
- A reduction of 'Other Income' – A\$ 472,000
- Increased staff costs – A\$ 657,000
- Savings from R&D rationalisation – A\$659,000

The Malaysian operations contributed a profit of A\$417,000 in the year ended 30 June 2010 compared to a profit of A\$53,000 in the year ended 30 June 2009.

INCOME STATEMENT

	2010 A\$ 000	2009 A\$ 000
Revenue	6,235	6,303
Other Income	495	967
Change in inventories of finished goods and work in progress	223	54
Raw Materials and consumables used	(2,415)	(2,263)
Employee benefits expense	(1,958)	(1,301)
Depreciation and amortisation expense	(255)	(147)
Impairment of non-current assets	(920)	-
Borrowing costs expense	(337)	(387)
Other expenses	(2,635)	(3,294)
Loss before income tax expense	(1,567)	(68)
Income tax expense	(6)	(3)
Net loss for the year	(1,573)	(71)
Other comprehensive income		
Exchange differences on translation of foreign operations	33	9
Total comprehensive loss for the year	(1,540)	(62)
Basic loss per share (cents per share)	1.304 cents	0.092 cents
Diluted loss per share (cents per share)	1.304 cents	0.092 cents

For personal use only

BALANCE SHEET

	2010 A\$ 000	2009 A\$ 000
CURRENT ASSETS		
Cash and cash equivalents	3,194	2,340
Trade and other receivables	1,471	1,224
Inventories	1,420	829
Other	33	-
TOTAL CURRENT ASSETS	6,118	4,393
NON-CURRENT ASSETS		
Property, plant and equipment	4,445	2,009
Intangible assets	22	-
TOTAL NON-CURRENT ASSETS	4,467	2,009
TOTAL ASSETS	10,585	6,402
CURRENT LIABILITIES		
Trade and other payables	759	916
Borrowings	2,558	2,514
Current tax liabilities	32	47
Other liabilities	1,011	898
TOTAL CURRENT LIABILITIES	4,360	4,375
NON-CURRENT LIABILITIES		
Borrowings	1,579	823
TOTAL NON-CURRENT LIABILITIES	1,579	823
TOTAL LIABILITIES	5,939	5,198
NET ASSETS	4,646	1,204
EQUITY		
Issued capital	7,554	2,572
Forex translation reserve	61	28
Accumulated losses	(2,969)	(1,396)
TOTAL EQUITY	4,646	1,204

For personal use only

STATEMENT OF CHANGES IN EQUITY

	Ordinary Shares A\$ 000	Accumulate d Losses A\$ 000	Other Reserve A\$ 000	Total A\$ 000
EQUITY				
Balance as at 1 July 2008	2,572	(1,325)	19	1,266
Loss for the year	-	(71)	-	(71)
Shares issued during the year	-	-	-	-
Exchange differences arising on translation of foreign operations	-	-	9	9
Balance as at 30 June 2009	<u>2,572</u>	<u>(1,396)</u>	<u>28</u>	<u>1,204</u>
Balance as at 1 July 2009	2,572	(1,396)	28	1,204
Loss for the year	-	(1,573)	-	(1,573)
Shares issued during the year	4,982	-	-	4,982
Exchange differences arising on translation of foreign operations	-	-	33	33
Balance as at 30 June 2010	<u>7,554</u>	<u>(2,969)</u>	<u>61</u>	<u>4,646</u>

For personal use only

STATEMENT OF CASH FLOWS

	2010 A\$ 000	2009 A\$ 000
CASH FLOWS FROM OPERATING ACTIVITIES		
Receipts from customers	6,292	6,326
Payments to suppliers and employees	(8,122)	(6,120)
Interest received	50	-
Finance costs	(337)	(371)
Government grant	157	454
Income tax paid	(21)	-
Net cash (used in)/generated from operating activities	(1,981)	289
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of property, plant and equipment	(10)	(82)
Cash acquired on acquisition of subsidiary	408	-
Net cash generated from/(used in) investing activities	398	(82)
CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from issue of shares	2,975	-
Costs of share issue	-	-
Funds held as security deposit	-	-
Proceeds from borrowings	309	553
Repayment of borrowings	(1,080)	(476)
Net cash provided by financing activities	2,204	77
Net increase in cash held	621	284
Cash at the beginning of the financial year	1,755	1,462
Effect of currency fluctuations on cash	33	9
Cash at the end of the financial year	2,409	1,755

Reconciliation to Cash Flow Statement

For the purposes of the cash flow statement, cash and cash equivalents comprise cash on hand and at bank and investments in money market instruments, net of outstanding bank overdrafts.

Cash and cash equivalents as shown in the statement of cash flows is reconciled to the related items in the statement of financial position as follows:

Cash and cash equivalents as per balance sheet	3,194	2,340
Bank overdraft	(785)	(585)
Cash and cash equivalents as per cash flow statement	2,409	1,755

NOTES

1 BASIS OF PREPARATION

The preliminary final report of Holista CollTech Limited for the year ended 30 June 2009 does not include all notes of the type normally included within the annual financial report and therefore can not be expected to provide as full an understanding of the financial performance, financial position and cash flow of the company as the full financial report.

(a) Basis of accounting

The preliminary final report has been prepared on an accruals basis and is based on historical costs modified by the revaluation of selected non-current assets, financial assets and financial liabilities, which the fair value basis of accounting has been applied.

All amounts are presented in Australian dollars, unless otherwise stated.

On 10 July 2009, Holista Biotech Sdn Bhd of Malaysia completed a reverse take-over of Colltech Australia Ltd. In this situation it is the continuing company's accounts that form the basis of the consolidation and therefore the comparative figure for the previous year reflect the Malaysia company and its subsidiaries' results only.

Unless otherwise detailed in this note, accounting policies have been consistently applied by the Company and are consistent with those applied in the 30 June 2009 annual report.

2 REVENUE

	2010	2009
	A\$ 000	A\$ 000
Operating activities		
Sale of goods	6,235	6,303
Interest received on deposits	50	236
Income – government assistance	430	474
Profit on disposal of PPE	-	245
Other	15	12
	6,730	7,270

3 FINANCIAL RESULTS

The group recorded a net loss of A\$1,540,000 for the year ended 30 June 2010 compared to a net loss of A\$62,000 for the year ended 30 June 2009.

The decline was mainly attributed to :-

	A\$ 000
-The write down of intangible asset due to the expiry of several patents	920
-A reduction of 'Other Income'	472
-Increased staff costs	657
-Savings from R & D rationalisation	659

4 RECONCILIATION OF CASH FLOW FROM OPERATIONS WITH PROFIT / (LOSS) AFTER INCOME TAX

Reconciliation of loss for the year to net cash used in operating activities :	2010	2009
	A\$ 000	A\$ 000
Net Loss	(1,573)	(71)
Adjustments for non-cash items :		
Depreciation	255	147
Profit on disposal of asset	-	(245)
Impairment of intangible asset	920	-
		-
(Increase)/decrease in assets :		
Receivables	(296)	(324)
Inventories	(591)	330
Other Assets	33	(543)
Increase/(decrease) in liabilities :		
Trade and other creditors	(729)	995
Net cash (used in)/generated from operating activities	(1,981)	289

5 DISCONTINUED OPERATIONS

There were no entities over which control was gained or lost during the year.

6 DETAILS OF INDIVIDUAL AND TOTAL DIVIDENDS AND DIVIDEND PAYMENTS

Date the final dividend is payable N/A

Record date to determine entitlements to the dividend N/A

Has the dividend been declared? N/A

Other disclosures in relation to dividends

The Directors have not declared a dividend and no dividends have been paid during the year.

7 NET ASSET BACKING

	2010 Cents per share	2009 Cents per share
Net tangible assets per share	3.568	1.563

For personal use only

8 CONTINGENT LIABILITY

There are no known contingent liabilities.

9 SEGMENT REPORTING

Following the reverse take-over, all trading has been conducted from Malaysia, and only ongoing maintenance and R & D activities within Australia.

10 ISSUED AND QUOTED SECURITIES AT END OF CURRENT PERIOD

Category of securities	Total number	Number quoted
Ordinary securities	129,603,281	52,603,281

11 EARNINGS PER SHARE (EPS)

2010

2009

Reconciliation of earnings to profit or loss

Profit /(loss)	(1,572,895)	(71,032)
Earnings used to calculate basic EPS	<u>(1,572,895)</u>	<u>(71,032)</u>
Earnings used in the calculation of dilutive EPS	<u>(1,572,895)</u>	<u>(71,032)</u>
	No. of shares	No. of shares
Weighted average number of ordinary shares outstanding during the year used in calculating basic EPS	<u>120,602,915</u>	<u>77,000,000</u>
Weighted average number of ordinary shares outstanding during the year used in calculating dilutive EPS	<u>120,602,915</u>	<u>77,000,000</u>

12 DETAILS OF CONTROLLED ENTITIES

Holista Biotech Sdn Bhd and its subsidiaries.
 Wholly owned.

13 ASSOCIATES AND JOINT VENTURES

The Company has no associates or joint ventures.

14 OTHER SIGNIFICANT INFORMATION

N/A

15 FOREIGN ENTITIES

The Company is an Australian entity and reports under Australian accounting standards.

16 AUDIT DISPUTES AND QUALIFICATIONS

There are no known audit disputes or qualifications.

17 STATEMENTS IN RELATION TO ACCOUNTS AND AUDIT

This report is based on accounts to which one of the following applies.

- | | | | |
|-------------------------------------|--|--------------------------|--|
| <input type="checkbox"/> | The accounts have been audited (refer audit attached report). | <input type="checkbox"/> | The accounts have been subject to review (refer attached review report). |
| <input checked="" type="checkbox"/> | The accounts are in the process of being audited or subject to review. | <input type="checkbox"/> | The accounts have <i>not</i> yet been audited or reviewed. |



Sign here:
(Company Secretary)

Date: ...31 August 2010

Print name: Ben Donovan

For personal use only